President Trump supports a bipartisan bill or the Foreign Investment Risk Review Modernization Act.

Charlene Vos

2018-07-21 13:35:00 Sat ET

President Trump supports a bipartisan bill or the Foreign Investment Risk Review Modernization Act (FIRRMA), which effectively broadens the jurisdiction of the Committee on Foreign Investments (CFIUS). This legislation gives CFIUS greater legal power to probe-and-block the acquisition of U.S. firms by foreign companies. The Trump administration advocates the fact that an expansion of CFIUS can be a powerful safety valve for future economic prosperity. In effect, this safety valve better protects the crown jewels of American technology and intellectual property from unfair trade transfers and corporate acquisitions that may threaten American national economic security.

In March 2018, CFIUS rejected the Singaporean rival Broadcom's M&A takeover of Qualcomm (a San Diego chipmaker) over 5G national security concerns. In mid-2018, CFIUS refused to approve a $1.2 billion M&A deal between MoneyGram (a Dallas money transfer company) and Ant Financial Group (a Chinese electronic-payments company). Also, CFIUS blocked the proposal from East Asian buyers to acquire a controlling equity stake in the Californian automobile LED business of the Dutch electronics giant Philips.

The new legislation grants CFIUS greater legal power to review foreign capital investment transactions beyond national economic security to U.S. competitive advantage in new industries such as 5G telecommunication and LTE broadband. Under this legislation, CFIUS can review major foreign capital investments, M&As, joint ventures, and strategic alliances that might involve the potential transfer of American critical technologies.

In accordance with the congressional mandate, CFIUS helps curb Chinese capital investments in American critical technologies that may hinder U.S. competitive advantage in emerging-industries due to national economic security concerns.

CFIUS prevents China and several other countries such as Russia, Japan, and Germany from exploiting loopholes in the current safeguards in order to acquire both sensitive and exclusive critical technologies, patents, and trademarks to the detriment of U.S. firms and inventors.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom.

Chanel Holden

2020-06-24 09:32:00 Wednesday ET

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom.

Several business founders and entrepreneurs take low risks with high potential rewards to buck the conventional wisdom. Renee Martin and Don Martin (2010

+See More

PwC releases a new study of top innovators worldwide as of November 2018.

Daphne Basel

2018-11-07 08:30:00 Wednesday ET

PwC releases a new study of top innovators worldwide as of November 2018.

PwC releases a new study of top innovators worldwide as of November 2018. This study assesses the top 1,000 global companies that spend the most on R&D

+See More

The U.S. further derisks and decouples from China.

Peter Prince

2023-05-31 03:15:40 Wednesday ET

The U.S. further derisks and decouples from China.

The U.S. further derisks and decouples from China.   Why does the U.S. seek to further economically decouple from China? In recent times, th

+See More

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

Monica McNeil

2019-04-01 08:28:00 Monday ET

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Smart firms and customers connect the continuous flow of lean production to the lean consumption of cost-effective minimum viable products.

Olivia London

2020-07-26 15:29:00 Sunday ET

Smart firms and customers connect the continuous flow of lean production to the lean consumption of cost-effective minimum viable products.

Firms and customers create value and wealth together by joining the continual flow of small batches of lean production to the lean consumption of cost-effec

+See More